In a report issued on June 1, Jessica Fye from J.P. Morgan maintained a Buy rating on LAVA Therapeutics (LVTX – Research Report), with a price target of $18.00. The company's shares closed last Monday at $3.01, close to its 52-week low of $2.74. According to TipRanks.com, Fye is a 4-star analyst with an average return of 7.1% and a 50.0% success rate. Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and Lexicon Pharmaceuticals. Currently, the analyst consensus on LAVA Therapeutics is a Moderate Buy with an average price target of $21.50, which is a 601.5% upside from current levels.
https://www.tipranks.com/news/blurbs/j-p-morgan-thinks-lava-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more LAVA Therapeutics NV Charts.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more LAVA Therapeutics NV Charts.